Brian So, MD
Gastroenterology · Texarkana, TXNPI 1841499100
Payments from drug & device makers
Across 897 payments — averaging $31.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Evoke Pharma, Inc.$15K
- AbbVie$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Johnson & Johnson$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Pfizer$1K
- plus $4K from 33 others
What the payments were for
- Speaking & faculty fees$13,50048%
- Travel & lodging$4512%
- Food & beverage$14,01349%
- Education$3321%
- Gifts$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Evoke Pharma, Inc. | 22 | $14,726 |
| AbbVie(2 entities) | 260 | $3,971 |
| Takeda Pharmaceuticals U.S.A., Inc. | 140 | $1,822 |
| Johnson & Johnson | 80 | $1,415 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 73 | $1,218 |
| Pfizer | 87 | $1,057 |
| Gilead | 64 | $963 |
| Sanofi | 18 | $455 |
| Ardelyx, Inc. | 25 | $439 |
| Phathom Pharmaceuticals, Inc. | 16 | $293 |
| Lilly USA, LLC | 14 | $231 |
| Madrigal Pharmaceuticals | 8 | $191 |
| Intercept Pharmaceuticals, Inc. | 10 | $175 |
| Merck | 10 | $165 |
| Braintree Laboratories, Inc. | 9 | $139 |
| Ferring Pharmaceuticals Inc. | 7 | $121 |
| Axonics, Inc. | 2 | $93 |
| Nestle Healthcare Nutrition Inc. | 5 | $92 |
| Bristol Myers Squibb | 6 | $89 |
| Redhill Biopharma Inc. | 5 | $82 |
| UCB, Inc. | 5 | $68 |
| Alfasigma USA, Inc. | 4 | $60 |
| Regeneron Healthcare Solutions, Inc. | 3 | $52 |
| AstraZeneca | 2 | $48 |
| Amgen | 3 | $45 |
| Mauna Kea Technologies, Inc. | 2 | $39 |
| Medtronic | 2 | $38 |
| Ironwood Pharmaceuticals, Inc | 3 | $35 |
| Bioventus LLC | 1 | $29 |
| Daiichi Sankyo Inc. | 2 | $28 |
| Novo Nordisk | 1 | $21 |
| Enterra Medical, Inc. | 1 | $16 |
| Celltrion USA Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Ambu Inc. | 1 | $14 |
| Shionogi Inc | 1 | $14 |
| Organon | 1 | $13 |
| Echosens North America, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,311 in reported general payments places this provider in the 80th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 11 | $270,368 |
| XifaxanRifaximin | 55 | $157,398 |
| CreonLipase/Protease/Amylase | 29 | $114,822 |
| EntyvioVedolizumab | 12 | $100,414 |
| RinvoqUpadacitinib | 11 | $77,588 |
| ZenpepLipase/Protease/Amylase | 19 | $71,203 |
| LinzessLinaclotide | 87 | $51,447 |
| GimotiMetoclopramide Hcl | 24 | $51,352 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 404 | $26,089 |
| Mesalamine | 35 | $14,490 |
| Pantoprazole Sodium | 640 | $6,774 |
| AprisoMesalamine | 12 | $6,218 |
| Ursodiol | 39 | $5,250 |
| Dexlansoprazole DrDexlansoprazole | 15 | $4,794 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 22 | $3,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $963 | $270,36811 claims |
| AbbVieCreon, Rinvoq, Linzess | $3,971 | $243,857127 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Apriso, Plenvu | $1,218 | $166,41587 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $1,822 | $100,41412 claims |
| Evoke Pharma, Inc.Gimoti | $14,726 | $51,35224 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $121 | $3,63422 claims |
| Braintree Laboratories, Inc.Sutab | $139 | $3,28820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Texarkana
- Eric LawitzSan Antonio$59.5M
- George DuvallTyler$17.5M
- John FordtranDallas$9.9M
- Timothy RitterSouthlake$7.7M
- Parvez MantryDallas$6.4M
- Mazen NoureddinHouston$6.1M
- Nadege GunnWaco$5.7M
- Michael BrownDallas$5.5M
- James MaherHouston$5.3M
- Stephen HarrisonLive Oak$5.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.